Infection with SARS‐CoV‐2 within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab probably leads to lower infection with SARS‐CoV‐2 within 6 months compared with placebo (moderate certainty).
1 finding from 1 review
Development of clinical COVID‐19 symptoms within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab leads to lower development of clinical COVID‐19 symptoms within 6 months compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality within 6 monthsb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab showed no clear difference in all‐cause mortality within 6 monthsb compared with placebo (low certainty).
1 finding from 1 review
Admission to hospital within 6 monthsb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab may leads to lower admission to hospital within 6 monthsb compared with placebo (low certainty).
1 finding from 1 review
Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab showed no clear difference in adverse events: all grade within 6 monthsb compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events within 6 monthsb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab showed no clear difference in serious adverse events within 6 monthsb compared with placebo (low certainty).
1 finding from 1 review